Gilead Sciences Inc
Market cap $187.1B
$150.50
GILD
$150.50
+0.26% today
Buy with €1M virtual cash · No real money
Gilead Sciences Inc (GILD) is a publicly traded company listed on the XNAS. As of September 19, 2026, Invest's signal rates GILD a Buy, with the stock up 34% over the past year. You can practice trading GILD risk-free with €1,000,000 in virtual cash.
Key stats
As of September 19, 2026
Market Cap
$187.1B
Volume
16.5M
52-wk High
$157.29
52-wk Low
$108.46
Day High
$153.23
Day Low
$149.57
Revenue (TTM)
$30.5B
EPS (TTM)
$-2.67
Performance
1M
+2.0%
6M
+6.7%
1Y
+34.1%
Invest signal · GILD
BuyAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
GILD overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev +12.1%Revenue
$8BEPS (diluted)
$-8.45 per shareLatest GILD news
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
Zacks Investment Research · 11h ago
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
Zacks Investment Research · 11h ago
Should You Invest in the VanEck Biotech ETF (BBH)?
Zacks Investment Research · 2d ago
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient Demand
GlobeNewswire Inc. · 2d ago
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036, Driven by Next-Generation Innovation and Expanding Patient Access
GlobeNewswire Inc. · 2d ago
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees
17,000
30-Day Win Rate · GILD
12 days
11 days
Last 23 sessions
How to practice trading GILD
- 1
Use the GILD buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top GILD traders on Invest
Full leaderboardFrequently asked questions
Is GILD a good stock to buy right now?
As of September 19, 2026, Invest's signal rates GILD a Buy, based on its price trend, valuation, and fundamentals, with the stock up 34% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading GILD risk-free first.
What is Gilead Sciences Inc's (GILD) market cap?
Gilead Sciences Inc has a market capitalization of approximately $187.1B, on trailing-twelve-month revenue of about $30.5B.
How has GILD stock performed?
GILD is up 34% over the past year and up 7% over six months. Its 52-week range runs roughly from $108.46 to $157.29. Past performance doesn't predict future results.
How can I practice trading GILD for free?
On Invest you get €1,000,000 in virtual cash and can buy GILD at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.
Compare GILD with peers